Philipp Mandel1, Mike Wenzel1,2, Benedikt Hoeh1, Maria N Welte1, Felix Preisser1, Tahir Inam1, Clarissa Wittler1, Clara Humke1, Jens Köllermann3, Peter Wild3,4,5, Christoph Würnschimmel2,6, Derya Tilki6,7, Markus Graefen6, Luis A Kluth1, Pierre I Karakiewicz2, Felix K-H Chun1, Andreas Becker1. 1. Department of Urology, University Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt, Germany. 2. Cancer Prognostics and Health Outcomes Unit, Division of Urology, University of Montreal Health Center, Montreal, QC H2X3A4, Canada. 3. Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, 60590 Frankfurt, Germany. 4. Frankfurt Institute for Advanced Studies (FIAS), 60590 Frankfurt, Germany. 5. Wildlab, University Hospital Frankfurt MVZ GmbH, 60590 Frankfurt, Germany. 6. Martini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, 20251 Hamburg, Germany. 7. Department of Urology, University Hospital Hamburg-Eppendorf, 20251 Hamburg, Germany.
Abstract
BACKGROUND: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. METHODS: Between January 2017-June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. RESULTS: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7-10. CONCLUSIONS: Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.
BACKGROUND: To test the value of immunohistochemistry (IHC) staining in prostate biopsies for changes in biopsy results and its impact on treatment decision-making. METHODS: Between January 2017-June 2020, all patients undergoing prostate biopsies were identified and evaluated regarding additional IHC staining for diagnostic purpose. Final pathologic results after radical prostatectomy (RP) were analyzed regarding the effect of IHC at biopsy. RESULTS: Of 606 biopsies, 350 (58.7%) received additional IHC staining. Of those, prostate cancer (PCa) was found in 208 patients (59.4%); while in 142 patients (40.6%), PCa could be ruled out through IHC. IHC patients harbored significantly more often Gleason 6 in biopsy (p < 0.01) and less suspicious baseline characteristics than patients without IHC. Of 185 patients with positive IHC and PCa detection, IHC led to a change in biopsy results in 81 (43.8%) patients. Of these patients with changes in biopsy results due to IHC, 42 (51.9%) underwent RP with 59.5% harboring ≥pT3 and/or Gleason 7-10. CONCLUSIONS:Patients with IHC stains had less suspicious characteristics than patients without IHC. Moreover, in patients with positive IHC and PCa detection, a change in biopsy results was observed in >40%. Patients with changes in biopsy results partly underwent RP, in which 60% harbored significant PCa.
Authors: Benedikt Hoeh; Rocco Flammia; Lukas Hohenhorst; Gabriele Sorce; Francesco Chierigo; Zhe Tian; Fred Saad; Michele Gallucci; Alberto Briganti; Carlo Terrone; Shahrokh F Shariat; Markus Graefen; Derya Tilki; Luis A Kluth; Philipp Mandel; Felix K H Chun; Pierre I Karakiewicz Journal: Prostate Int Date: 2022-01-26
Authors: Rocco S Flammia; Benedikt Hoeh; Lukas Hohenhorst; Gabriele Sorce; Francesco Chierigo; Andrea Panunzio; Zhe Tian; Fred Saad; Costantino Leonardo; Alberto Briganti; Alessandro Antonelli; Carlo Terrone; Shahrokh F Shariat; Umberto Anceschi; Markus Graefen; Felix K H Chun; Francesco Montorsi; Michele Gallucci; Pierre I Karakiewicz Journal: Int Urol Nephrol Date: 2022-07-15 Impact factor: 2.266
Authors: Jens Köllermann; Benedikt Hoeh; Daniel Ruppel; Kevin Smith; Henning Reis; Mike Wenzel; Felix Preisser; Marina Kosiba; Philipp Mandel; Pierre I Karakiewicz; Andreas Becker; Felix K H Chun; Peter Wild; Luis A Kluth Journal: Virchows Arch Date: 2022-06-17 Impact factor: 4.535